This publication is intended as an educational resource for healthcare professionals. It summarises the risk factors and burden of disease associated with herpes zoster, as well as treatment options and clinical practice recommendations for prevention through vaccination. Clinical trial data for the two vaccines available for use in New Zealand, live attenuated herpes zoster vaccine (ZVL) and recombinant varicella zoster virus glycoprotein E vaccine (RZV), is then reviewed in detail.
This publication has been created with sponsorship from GSK. The content is entirely independent and based on published studies and the author’s opinions. It may not reflect the views of GSK. Please consult the full Data Sheets for any medications mentioned in this article at www.medsafe.govt.nz before prescribing. Treatment decisions based on these data are the full responsibility of the prescribing physician. All trademarks mentioned in this review are the property of their respective owners.
Please login below to download this issue (PDF)